Satori brings in $22M to stop Alzheimer’s in its tracks
Satori Pharmaceuticals, a company that says it’s developing drugs with the potential to actually stop Alzheimer’s disease in its early phases — an unprecedented claim — landed $22 million in second-round funding to push its products through a first battery of tests.
Based in Cambridge, Mass., the firm has broken away from the usual drugs, like Pfizer’s Aricept, that slow the symptoms but don’t address the base-level process of the disease. Most of these treatments have… Continue Reading
Life sciences briefing: Friday, Jan. 4, 2008
TODAY’S HEADLINES:
Follica pulls out $5.5M for hair loss (release)
WuXi PharmaTech to acquire AppTec Lab for $151 million (release)
U.S. Venture Partners names Laurence Lasky a venture partner (PDF release)
Burrill & Co. promotes several life-science VCs (release)
SV Life Sciences promotes Darren Black to partner (release)
Follica pulls out $5.5M for hair loss – Boston’s Follica, a biotech that aims to reverse hormone-related hair loss, raised $5.5 million in a first funding round. Investors included Interwest Partners and PureTech Ventures.
Follica… Continue Reading